DANNCE.AI is developing an AI biomarkers platform called DANNCE that digitizes clinical assessments to quantify movement and evaluate drug efficacy for neurological disorders. The platform uses AI to analyze patient videos and provides objective assessments, improving clinical decision-making and drug development.
Market
Neurological Care and Drug Development
Location
Boston,
Massachusetts,
United States
Coinvestors
Glasswing Ventures, The Leo Lion Company, Duke Capital Partners, Merck Digital Sciences Studio